biostudies-literatureYamamoto NSwim Across America (SAA)National Institutes of Health (NIH)NCI NIH HHSNational Institutes of HealthSwim Across America733-745https://www.ebi.ac.uk/biostudies/studies/S-EPMC11967372biostudies-literatureUnknown31(4)<h4>Purpose</h4>The purpose of this study was to establish HMGA2 as a marker of basal-like disease in pancreatic ductal adenocarcinoma (PDAC) and explore its use as a biomarker for prognosis and treatment resistance.<h4>Experimental design</h4>We identified high-mobility group A2 (HMGA2) protein expression in basal PDAC cells in a single-cell RNA sequencing (RNA-seq) atlas of 172 patient samples. We then analyzed HMGA2 expression, along with expression of the classic marker GATA-binding factor 6 (GATA6), in a cohort of 580 PDAC samples with multiplex IHC. We further supplemented these data with an additional 30 diverse patient samples and multiple independent single-cell RNA-seq databases.<h4>Results</h4>We found that expression of HMGA2, but not previously described basal markers cytokeraClinical cancer research : an official journal of the American Association for Cancer ResearchHMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma.PMC119673721R37CA241472P20 CA252733R01 CA223483U01 CA284086P30 CA015704R01 CA248917P50 CA285275R01 CA161112R01 CA286615R37 CA241472P50 CA272213Walsh TSafyan RAJang GHYamamoto NKugel SBolton NMDobersch SHaraguchi MSamraj ANHingorani SRVij KRDeNardo DGLi LNotta FMudd JLFields RCKang LICrawford HCSteele NGRuzinova MBChiorean EGLoveless IfalseHMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma.<h4>Purpose</h4>The purpose of this study was to establish HMGA2 as a marker of basal-like disease in pancreatic ductal adenocarcinoma (PDAC) and explore its use as a biomarker for prognosis and treatment resistance.<h4>Experimental design</h4>We identified high-mobility group A2 (HMGA2) protein expression in basal PDAC cells in a single-cell RNA sequencing (RNA-seq) atlas of 172 patient samples. We then analyzed HMGA2 expression, along with expression of the classic marker GATA-binding factor 6 (GATA6), in a cohort of 580 PDAC samples with multiplex IHC. We further supplemented these data with an additional 30 diverse patient samples and multiple independent single-cell RNA-seq databases.<h4>Results</h4>We found that expression of HMGA2, but not previously described basal markers cytokera2025-01-01T00:00:00Z2025 Feb2026-05-29T17:23:05.691Z2026-04-08T05:36:28.615ZS-EPMC119673723968002110.1158/1078-0432.CCR-24-220010.1158/1078-0432.ccr-24-2200